The combination of an elevated concentration of CLB intracellularly with another kind of pro-apoptotic drug not dependent on surviving genes, could not only enhance their respective cancer killing activities but perhaps make a resistant lymphoma cell sensitive again. Here, CLYBL is linked to cancer.